Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05147831 · ClinicalTrials.gov registry record · NA

Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.

A NA study of Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI) and Contrast-induced Nephropathy Following Coronary Angiogram (CIN), sponsored by The University of Texas Medical Branch, Galveston.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT05147831: Recruiting NA study of Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI) and Contrast-induced Nephropathy Following Coronary Angiogram (CIN), sponsored by The University of Texas Medical Branch, Galveston.

NCT05147831 is a NA study of Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI) and Contrast-induced Nephropathy Following Coronary Angiogram (CIN) that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05147831, a NA study of Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI) and Contrast-induced Nephropathy Following Coronary Angiogram (CIN), is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The use of imaging is increasing in clinical practice, either for diagnosis or intervention. In these imaging processes, contrast medium (CM) is widely used. However, CM administration can induce contrast-induced nephropathy (CI-AKI). CI-AKI is the third most common cause of renal insufficiency, and its incidence varies from 2% to 50% depending on patient risk factors; in addition, studies have shown that CI-AKI occurs in 2% to 25% of patients undergoing coronary intervention. CI-AKI is associated with significant mortality and morbidity in patients undergoing coronary angiography or other diagnostic contrast studies. We assessed the latest promising evidence on the ability of remote ischemic preconditioning (RIPC) to reduce the incidence of CI-AKI in patients undergoing Coronary Angiogram (CA) or diagnostic contrast studies such as CT angiogram, while at the same time being a non-invasive, low cost, easy, and safe method with absence of adverse effects. However, more randomized controlled trials are needed to confirm these preliminary results. The aim of this study is to minimize the incidence of CI-AKI at the University of Texas Medical Branch (UTMB). If found to be an effective method, RIPC would help minimize the incidence of CI-AKI in all institutions across the globe, who would adopt this intervention. The primary objective: i) reduce the rise in creatinine to \< 0.5 mg/dL post-CA in moderate to high risk patients and ii) reduce the incidence of renal replacement therapy post-CA in moderate to high risk patients; iii) we also aim to establish that RIPC is safe and effective. We hypothesize that the use of RIPC, when added to standard medical therapy (pre-and post-CA hydration), will mitigate the effects of contrast on the renal vasculature and lessen the incidence of CI-AKI in moderate to high risk patients at the University of Texas Medical Branch. The use of iodinated contrast to visually enhance target vasculature is a widely used diagnostic technique t

Primary Outcome

The primary outcome would be the incidence of CI-AKI, which is defined as an increment of serum creatinine ≥ 0.5 mg/dL or a relative increase of ≥ 25% over the baseline value within a period of 48-72 hours after contrast medium administration.

Interventions

  • OTHER Remote Ischemic Preconditioning

Study Locations (1)

Texas

  • University of Texas- Medical Branch (UTMB) - Galveston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-11-30
Est. Completion 2027-11-30
Phase NA

What NCT05147831 shows while recruiting

NCT05147831 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI) appearing as the primary indexed condition, and to 1 intervention - of which Remote Ischemic Preconditioning is the first listed.

NCT05147831 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05147831 about?

NCT05147831 is a clinical study titled "Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.". The use of imaging is increasing in clinical practice, either for diagnosis or intervention. In these imaging processes, contrast medium (CM) is widely used. However, CM administration can induce contrast-induced nephropathy (CI-AKI). CI-AKI is the third most common cause of renal insufficiency, and...

What is the current status of trial NCT05147831?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2021-11-30. Estimated completion is 2027-11-30.

What conditions does trial NCT05147831 study?

This clinical trial studies the following conditions: Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN).

What interventions are being tested in trial NCT05147831?

The interventions under investigation include: Remote Ischemic Preconditioning (OTHER).

Who is sponsoring clinical trial NCT05147831?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05147831 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT05147831's enrollment target sits among peer trials

300 330th of 2000 higher than 1,630 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05147831, the US trial registry maintained by the National Library of Medicine. NCT05147831 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.